secwatch.observer — SEC 8-K summary
======================================

Issuer:     TITAN PHARMACEUTICALS INC (—)
CIK:        0000910267
Form:       8-K
Filed at:   2023-07-28T23:59:59+00:00
Accession:  0001829126-23-004963
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.03, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Titan Pharmaceuticals sells addiction-product portfolio to Fedson for $2M upfront plus up to $50M milestones
--------------------------------------------------------------------------------

- Asset sale includes Probuphine and Nalmefene implant programs for addiction treatment.
- Upfront payment $2M ($1M at close, $1M escrow); potential milestones up to $50M plus single-digit royalties.
- Fedson assumes pending employment-related liability; close expected 10 days after July 26 signing.
- CEO David E. Lazar provides Titan $250K unsecured promissory note at Prime+2%, due Jan 1, 2024 or upon financing.
- Titan grants 450,000 unrestricted shares to board and management, vested immediately.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/910267/000182912623004963/0001829126-23-004963-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/910267/000182912623004963/titanpharma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-23-004963

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer